Medical/Pharmaceuticals

SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly

-Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company ("...

2025-11-08 18:00 1645

2025 Aurora Prize for Awakening Humanity Awarded to Dr. Jamal Eltaeb

Head of Al Nao Hospital in Sudan recognized for sustaining critical medical care amid civil war and saving hundreds of lives NEW YORK, Nov. 8, 2025 /PRNewswire/ -- The Aurora Humanitarian Initiative announced Thursday evening thatDr. Jamal Eltaeb

2025-11-08 00:03 806

Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025

Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precis...

2025-11-07 22:05 3151

HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers

Late-breaking poster presentations show HCB101's favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 7, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a ...

2025-11-07 22:00 3597

Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine

* Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and therapeutic vaccination towards the HBV functional cure strategy DURHAM, N.C. and BEIJING, Nov. 7, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," or the "Com...

2025-11-07 21:30 2136

Coreline Soft Unveils AVIEW 2.0 at RSNA 2025: Next-Generation AI Platform Redefining Radiology Workflow Standards

CHICAGO and SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Coreline Soft  will introduce its groundbreaking chest AI platform AVIEW 2.0 at RSNA 2025 (November 30–December 4, Chicago), demonstrating how unified AI automation is fundamentally trans...

2025-11-07 21:00 1650

EBR Systems Achieves First Enrollments in the WiSE-UP Study for Heart Failure Patients

The WiSE-UP post-approval study is gathering real-world evidence from commercially treated patients using the WiSE® left ventricular endocardial pacing (LVEP) system. Key Highlights: * The first two patients have now been enrolled in the WiSE-UP post-approval study by DrDevi Nair from St Bern...

2025-11-07 21:00 1181

Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress

* Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum phosphate levels was established and AP301's efficacy is sustained throughout the 52 weeks of treatment. * The non-inferiority of AP301 to sevelamer carbonate in redu...

2025-11-07 20:00 1425

Cranial Technologies Debuts NMPA-Cleared Infant Head Reshaping Treatment in China at CIIE

SHANGHAI, Nov. 7, 2025 /PRNewswire/ -- Cranial Technologies, a leading US medical device company specializing in the treatment of infant head shape conditions, officially introduced its flagship DOC Band® treatment in the Chinese market at the China International Import Expo (CIIE), taking place ...

2025-11-07 15:58 1257

Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 7, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, andEvinova, a global ...

2025-11-07 14:00 1624

Fosun International Honored with Gold Award and Best Sustainability Team at The Asset Corporate Sustainability Leadership Awards 2025

HONG KONG, Nov. 7, 2025 /PRNewswire/ -- On the evening of 6 November 2025, The Asset, a renowned Asian financial magazine, hosted "The Asset Corporate Sustainability Leadership Awards 2025" ceremony inSingapore. Fosun International Limited ("Fosun International" or the "Company") (HKEX stock cod...

2025-11-07 09:00 3751

Volpara Now Operates Under Lunit Brand, Advancing a Unified Vision for AI Cancer Intelligence

The rebranding marks the first phase of Lunit's unified global identity, connecting breast health, AI detection, and precision oncology under one name. SEOUL, South Korea, Nov. 6, 2025 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and therapeutics, today ann...

2025-11-07 08:14 1264

ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut

SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that the Company will ...

2025-11-07 08:10 1458

Australian Sleep Tech Company Launches a Smart Ring to Transform Sleep & Health - retimer Ring

ADELAIDE, Australia, Nov. 7, 2025 /PRNewswire/ -- Re-Time Pty Ltd (RTPL) today announced the launch of the retimer Ring, the first smart ring solution developed by an Australian company to help people improve sleep and overall wellbeing. Building on a legacy of more than 25 years of research at F...

2025-11-07 07:00 1606

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

BELLEVUE, Wash., Nov. 6, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced the key findings from a company-sponsored pilot study conducted by Woori IO, an OSR Company, in collaboration with Korea University Guro Hospital. The study, which took place fromMay 9 to September 12,...

2025-11-06 21:30 1544

Leading Fertility Specialist Associate Professor Gavin Sacks joins Genea

SYDNEY, Nov. 6, 2025 /PRNewswire/ -- Genea Fertility, Australia's pioneering fertility network, is pleased to announce the appointment of internationally renowned fertility specialist, Associate ProfessorGavin Sacks, to its medical leadership team, continuing the organisation's 40-year tradition ...

2025-11-06 16:09 1228

International Symposium on Myofunctional Therapy Concludes Successfully in Shanghai, Strengthening Global Collaboration in Functional Orthodontics

SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- The International Symposium on Myofunctional Therapy in Multidisciplinary Collaboration, hosted by the Chinese Association of Orofacial Myology (CHAOM) and supported by Smartee Denti-Technology, concluded successfully inShanghai. The event brought together ...

2025-11-06 15:35 1446

Fosun Marks Eighth Year at CIIE, Guo Guangchang Calls for More Cutting-Edge Innovation

HONG KONG, Nov. 6, 2025 /PRNewswire/ -- On 5 November 2025, the 8th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center (Shanghai). As a "full-attendance" exhibitor for eight consecutive years, Fosun, together with its overseas member companies and glob...

2025-11-06 15:19 2897

Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy

Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines". LOS ANGELES, Nov. 6, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific breakthro...

2025-11-06 14:11 1437

THE ADECCO GROUP Q3 2025 RESULTS

AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange Strong share gains, good growth and improved profit margin ZURICH, Nov. 6, 2025 /PRNewswire/ --   HIGHLIGHTS * Further strong market share gains, Group +375 bps and Adecco +300 bps * Group revenues +3.4% yoy, and +3...

2025-11-06 13:45 1043
1 ... 32333435363738 ... 645